The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

News

Syndicate content
04/03 Orphan Drug Designation for Gallium-68
The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors.
04/03 NET Leader Named to Prestigious PCORI Panel
We are pleased to announce that Josh Mailman, President of the NorCal CarciNET community and chairman of the Society of Nuclear Medcine and Molecular Imaging's Patient Advisory Board has been appointed to the Patient-Centered Outcomes Research Institute's (PCORI) newest panel on Rare Diseases.
04/03 Congrats to our Cycle for Survival Teams!
We would like to offer a big congratulations to our two Cycle for Survival teams who knocked their fundraising goals out of the park! The first team, captained by Dave McCoy has raised a combined total of $65,000, cycling in both New York City and Boston; while Hap Rowan's team in New York City managed to raise over $20,000! All money will go towards supporting NET cancer research.
04/02 $300 Thousand in Prizes to Spur Creation of Neuroendocrine Cancer Cell Lines

The Rare Cancer Research Foundation (RCRF) and Caring for Carcinoid Foundation (CFCF) announced up to $300 thousand in prize awards to researchers to develop cell lines for intestinal carcinoid and pancreatic neuroendocrine cancer. 

03/12 Health Insurance in Transition: Protecting NET Patients
Health insurance is undergoing a major transition in the US. Many changes are taking place: new plans are being offered while other plans are no longer available.
03/10 First Ever NET Cancer Survey

Please help the Caring for Carcinoid Foundation and the  Carcinoid Cancer  Foundation - both members of the International  Neuroendocrine Cancer Alliance (INCA) -- increase awareness and education about NET worldwide by completing the first ever global survey of NET cancer patients! 

03/10 Exciting Collaboration with RCRF
The lack of widely available neuroendocrine cancer cell lines is a major obstacle to neuroendocrine cancer research.  Multiple cell lines that reliably recapitulate the behavior of neuroendocrine cancers are critically needed in order to move many necessary elements of carcinoid and neuroendocrine cancer research. 
03/10 In Memoriam

Two dear friends and long time supporters of CFCF passed away in January.  As they battled their disease over the years, both were pillars of strength and inspiration to so many in their communities. Our hearts go out to their family and friends.  They will be sorely missed.

02/10 2013: A Year in Review
2013 was quite a busy, productive, and exciting year for the Caring for Carcinoid Foundation (CFCF). Here is a brief recap of some of the highlights of 2013, which you can find in further detail in Executive Director Ron Hollander's latest blog post

01/17 Phase II CAPTEM Study Presented at ASCO GI Symposium

Robert L. Fine, MD presented encouraging results from a phase II clinical trial using a combination of temozolomide and capecitabine, or CAPTEM, in patients with various types of neuroendocrine tumors at the ASCO GI conference in San Francisco, CA yesterday.  

Get the facts on pancreatic neuroendocrine cancer

Make a Difference Get Involved Today

Sign-up for our e-Newsletter.

Tell Your Story

Sign-up for our e-Newsletter.

E-update Archive

video

Latest Video

Check out the CFCF video library.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

video

Latest Video

Check out the CFCF video library.

Connect with CFCF online:
FacebookTwitterYouTube

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange      

Seal Exchange